

Reference: FOI 24240 GLO 11M

Subject: Lynch Syndrome

QUESTION	RESPONSE
<p>Could you select the answers to the written questions below:</p>	
<p>1. Do you commission first line screening e.g. full 4 antibody IHC and/or MSI for molecular features of Lynch syndrome in all newly diagnosed bowel cancer patients?</p> <ul style="list-style-type: none"> • Yes, this test is commissioned for all bowel cancer patients as per DG27 NICE guidance. • Yes, but it is only commissioned in bowel cancer patients aged under 50 years at diagnosis - please specify why the guidance has not been implemented. • No, we do not commission this test – please specify why. • Other commissioning strategy – please provide information. 	<p>Specialist clinical genomic services, including cancer genetics, are not commissioned locally but instead form part of the Prescribed Specialised Services commissioned by NHS England (NHSE).</p> <p>May we suggest you contact NHSE directly. Please find their contact details below:</p> <p>NHS England PO Box 16738 Redditch B97 9PT</p> <p>Email: england.contactus@nhs.net Website: https://www.england.nhs.uk/contact-us/foi/</p>

<p>2. If first line screening is currently commissioned (either in all cases or as a subset) are second and third line genomic tests being commissioned in cases of MLH1 loss i.e. BRAF mutation and MLH1 promoter methylation, as per DG27 NICE guidance?</p> <ul style="list-style-type: none"> • Both BRAF mutation and MLH1 promoter methylation are commissioned. • Only BRAF mutation is commissioned. • Only MLH1 promoter methylation is commissioned. • Neither is commissioned. Please specify why. 	
<p>3. If the full NICE guidance (DG27) is not currently implemented, do you intend to commission screening for molecular features of Lynch syndrome in all newly diagnosed bowel cancer patients across your area?</p> <ul style="list-style-type: none"> • Yes, we intend to commission universal testing as per DG27. • No, we do not intend to commission DG27 – please provide information on why. 	

The information provided in this response is accurate as of 15 January 2018, and has been authorised for release by Ellen Rule, Director of Transformation & Service Redesign for NHS Gloucestershire CCG.